<DOC>
	<DOCNO>NCT01621542</DOCNO>
	<brief_summary>This clinical study design evaluate safety , immunogenicity antitumor activity WT2725 . WT2725 administer patient advanced malignancy know overexpress WT1</brief_summary>
	<brief_title>Clinical Study WT2725 Patients With Advanced Malignancies</brief_title>
	<detailed_description>Treatment WT1 vaccine clinical trial show evidence immunogenicity clinical response various malignancy . This study assist determine dose level ( ) use future clinical study evaluate clinical immunological response .</detailed_description>
	<criteria>Part 1 Patient must Eastern Cooperative Oncology Group ( ECOG ) Performance Score 0 , 1 , 2 Patient must one follow histologically cytologically document measurable ( may measureable tumor marker , quantitative RTPCR WT1 transcript AML , CA125 ovarian carcinoma ) advance stage malignancy : nonsmall cell lung , ovarian , glioblastoma , AML ( include acute promyelocytic leukemia ) , know overexpress WT1 protein . Patient must qualify study specific HLA typing assay . Haematological parameter : Absolute neutrophil count ( ANC ) ≥ 1,000/μl Platelet count ≥ 10.0x10 ( 4th power ) /μl ( ≥ 5.0 x 10 ( 4th power ) /μl stem cell transplant ) Hemoglobin ≥ 9.0 g/dL Absolute lymphocyte count ( ALC ) ≥ 1,000/μl ( ≥ 500/μl stem cell transplant ) Note : After completion dose escalation , patient AML require meet hematologic criterion . Biochemical Parameters : serum creatinine ≤ 1.5x upper limit normal ( ULN ) reference lab . total bilirubin ≤ 2.0 mg/dl ( ≤ 3.0 mg/dl patient know Gilbert 's syndrome ) alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤ 3 time ULN reference lab Patient must access archival tumor tissue sample agree undergo biopsy study eligibility confirm obtain fresh sample evaluation WT1 expression . In place archival tumor tissue sample , subject AML available bone marrow aspirate and/or , bone marrow biopsy , PCR WT1 transcript perform first dose study drug . Note : The archived tumor tissue sample need deliver clinical site prior enrollment patient , however availability confirm provision accession number identification number . Patient Inclusion Criteria Part 2 : Patient legal representative must give write informed consent privacy authorization prior participation study . Patient must willing able comply study procedure visit schedule must able follow verbal write instruction . Patient must ≥ 18 year age . Women childbearing potential men female sexual partner childbearing potential must agree abstain sexual intercourse use double barrier method determine woman childbearing potential ( http : //www.nccn.org/professionals/physician_gls/f_guidelines.asp ) . Patient must ECOG Performance Score 0 , 1 , 2 ( refer Appendix II ) . Patient life expectancy least 4 month . Patient must histologically cytologically document measurable ( may measurable tumor marker , quantitative RTPCR WT1 transcript AML ) advance stage glioblastoma AML ( include acute promyelocytic leukemia ) , know overexpress WT1 protein . Note : Determination WT1 expression assess prior patient enrollment . Patient must advance stage malignancy define meet least one follow criterion : progress recur despite standard therapy standard therapy exist patient intolerant standard therapy patient candidate standard therapy Patient must HLAA*0201+ and/or HLAA*0206+ Patient glioblastoma must adequate bone marrow immune reserve , document : ANC ≥ 1000/μl ( ≥ 500/μl stem cell transplant ) Platelet count ≥ 10.0 x 1 ( 4th power ) /μl ( ≥ 5.0 x 10 ( 4th power ) /μl stem cell transplant ) Hemoglobin ≥ 9.0 g/dL ALC ≥ 900/μl ( Note : Patients AML require meet hematologic criterion ) . Patient must adequate renal function document serum creatinine ≤ 1.5 time ULN reference lab . Patient must adequate hepatic function document total bilirubin ≤ 2.0 mg/dl ( ≤ 3.0 mg/dl patient know Gilbert 's syndrome ) ALT AST ≤ 3 time ULN reference lab . Patient must access archival tumor tissue sample agree undergo biopsy study eligibility confirm obtain fresh sample evaluation WT1 expression . In place archival tumor tissue sample , patient AML available bone marrow aspirate and/or bone marrow biopsy PCR WT1 transcript perform first dose study drug . Note : The archived tumor tissue sample need deliver clinical site prior enrollment patient , however availability confirm provision accession number identification number . • Patients AML must willing undergo bone marrow aspiration/biopsy treatment indicator measureable disease . Part 1 Patient extensively disseminate primary glioblastoma . Patient symptomatic brain metastasis , ie , neurologically stable require treatment corticosteroid , central nervous system ( CNS ) leukemia . Patient infection require treatment systemic antibiotic antiviral medication complete treatment infection within 4 day prior plan initial dose WT2725 . Patient require systemic , pharmacologic dos corticosteroid ( equivalent &gt; 60 mg hydrocortisone/day 2 mg dexamethasone/day ) . Replacement dos ( equivalent ≤ 5 mg prednisone/day ) , topical , ophthalmic , inhalation steroid permit need . Patient positive test Hepatitis B surface antigen , Hepatitis C antibody , human immunodeficiency virus ( HIV ) 1 , HIV2 antibody , history positive result . Patient receive follow treatment within specify timeframe prior dosing : endocrine therapy , immunotherapy , transfusion , hematopoietic factor within 14 day prior plan first dose study drug ( Note : After completion dose escalation , patient AML require meet hematologic criterion , eg . transfusion hematopoietic growth factor . ) chemotherapy include moleculartargeting therapy within 21 day ( moleculartargeted agent associate myelosuppression immunosuppression , minimum interval 5 halflives less 21 day ) surgery , radiation , immunosuppressant within 28 day investigational drug within 28 day mitomycinC nitrosoureas within 42 day Patient unresolved ≥ Grade 2 AE previous antineoplastic treatment , exclude alopecia . Pregnant lactate woman Patient autoimmune condition Patients serious unstable medical illness Patient pleural effusion , ascites , pericardial fluid require drainage . Patient staff member sponsor clinical site involve conduct study relative staff member . Patient Exclusion Criteria Part 2 : Patient extensively disseminate primary glioblastoma . Patient symptomatic brain metastasis , ie , presence neurological symptom require treatment corticosteroid , CNS leukemia . Patient infection body temperature &gt; 38.3˚C within 48 hour prior plan first dose study drug . Patient require systemic , pharmacologic dos corticosteroid ( equivalent &gt; 60 mg hydrocortisone/day 2 mg dexamethasone/day ) . Replacement dos ( equivalent ≤ 5 mg prednisone/day ) , topical , ophthalmic , inhalation steroid permit need . Patient positive test Hepatitis B surface antigen , Hepatitis C antibody , HIV1 , HIV2 antibody , history positive result . Patient receive follow treatment within specify timeframe : endocrine therapy , immunotherapy , transfusion , hematopoietic factor within 14 day prior plan first dose study drug ( Note : Patients AML require meet hematologic criterion , eg , transfusion hematopoietic growth factor . ) , chemotherapy include moleculartargeting therapy within 21 day prior plan first dose study drug ( moleculartargeted agent notis 5 halflives less 21 day ) , surgery , radiation , immunosuppressant within 28 day prior plan first dose study drug , investigational drug within 28 day prior plan first dose study drug , mitomycinC nitrosoureas within 42 day prior plan first dose study drug . Note : Patients receive LHRH agonist antagonists antiestrogens aromatase inhibitor start stable dose least 90 day prior plan first dose study drug eligible . Patients permit one 28 day cycle concurrent treatment hydroxyurea study . Patient unresolved ≥ Grade 2 AE previous antineoplastic treatment , exclude alopecia . Woman pregnant lactate positive pregnancy test screening . If woman positive pregnancy test , evaluation may conduct rule ongoing pregnancy allow patient eligible . Patient autoimmune condition , include , limited , multiple sclerosis , Grave 's disease , vasculitis , systemic lupus erythematosus , rheumatoid arthritis , systemic sclerosis , myasthenia gravis , ankylose spondylitis , Wegener 's granulomatosis , ulcerative colitis , Crohn 's disease , psoriasis require systemic therapy , pemphigus , temporal arteritis , dermatomyositis , Sjögren 's syndrome , Goodpasture 's syndrome , interstitial pneumonitis , interstitial nephritis , HenochSchönlein purpura . Patient opinion investigator intercurrent condition could preclude participation study , pose undue medical hazard , could interfere interpretation study result , include , limited , patient congestive heart failure ( NYHA Class III IV ; refer Appendix III ) , unstable angina , cardiac arrhythmia require treatment , recent ( within prior 6 month ) myocardial infarction , acute coronary syndrome stroke , severe obstructive pulmonary disease , hypertension require than2 medication adequate control , diabetes mellitus 2 episode ketoacidosis prior 12 month . Patient pleural effusion , ascites , pericardial fluid require drainage . Note : Patient drain removal ≥ 14 day prior plan first dose study drug sign worsen eligible . Patient medical , psychiatric , social condition , include substance abuse opinion investigator would preclude participation study . Patient previous treatment study drug WT1related vaccine therapy . Patient known hypersensitivity component study drug . Patient staff member sponsor clinical site involve conduct study relative staff member</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Oncology</keyword>
	<keyword>Malignancies</keyword>
	<keyword>Wilms ' Tumor</keyword>
	<keyword>WT1</keyword>
	<keyword>Ovarian</keyword>
	<keyword>Glioblastoma [ GBM ]</keyword>
	<keyword>Acute myeloid leukemia [ AML ]</keyword>
</DOC>